

August 4, 2022



Forward-Looking Statements

https://ir.biocryst.com/financial-information/sec-filings

BioCryst's presentation may contain forward-looking statements, including statements regarding future results, unaudited and forward-looking financial information and company performance or achievements. These statements are subject to known and unknown risks and uncertainties which may cause our actual results, performance or achievements to be materially different from any future results or performances expressed or implied in this presentation. You should not place undue reliance on the forward-looking statements. For additional information, including important risk factors, please refer to BioCryst's documents filed with the SEC and located at



Agenda



◆ Corporate Update:

Jon Stonehouse – President and Chief Executive Officer

- ◆ ORLADEYO® (berotralstat) Launch Update: Charlie Gayer – Chief Commercial Officer
- ◆ Financial Update
 Anthony Doyle Chief Financial Officer
- ◆ BCX9930 Update
 Dr. Helen Thackray Chief Research and Development Officer
- Summary and Q&A

Finance Summary

(figures in millions)

2Q22 Cash Position

Cash, cash equivalents, restricted cash & investments at June 30, 2021	\$223
Cash, cash equivalents, restricted cash & investments at June 30, 2022	\$419
Senior Credit Facility ^A	\$151

Proforma cash, cash equivalents, restricted cash & investments at June 30, 2022 ^B	\$492 ^C
Proforma Senior Credit Facility ^B	\$226

A - From Athyrium Capital Management, term loan of \$125M interest-only for 5-year term, \$25.8 in interest payment-in-kind (PIK) has been added to principal since issuance

2022 FY Guidance

ORLADEYO Revenue	\$255 - \$265
Operating Expenses (excluding non-cash comp)	\$390 - \$400



B – On July 29, 2022 the Company completed the delayed draw of \$75M under term loan B and C with Athyrium Capital Management.

C – Approximately



August 4, 2022

